---
title: "EU Approves Ionis Pharmaceuticals' DAWNZERA for Hereditary Angioedema Prevention"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/273226026.md"
datetime: "2026-01-21T12:00:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273226026.md)
  - [en](https://longbridge.com/en/news/273226026.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273226026.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/273226026.md) | [English](https://longbridge.com/en/news/273226026.md)


# EU Approves Ionis Pharmaceuticals' DAWNZERA for Hereditary Angioedema Prevention

Ionis Pharmaceuticals Inc. and Otsuka Pharmaceutical Co., Ltd. announced that the European Commission has approved DAWNZERA™ (donidalorsen) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older in the European Union. The approval is based on positive results from the Phase 3 OASIS-HAE and OASISplus studies, where DAWNZERA demonstrated a significant reduction in HAE attack rates. Otsuka holds exclusive rights to commercialize DAWNZERA in Europe and Asia Pacific. With this approval, Ionis is eligible for a milestone payment of $15 million and tiered royalties up to 30% on net product sales. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260119050072) on January 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### 相關股票

- [Otsuka Pharmaceutical (OTSKY.US)](https://longbridge.com/zh-HK/quote/OTSKY.US.md)
- [Ionis Pharma (IONS.US)](https://longbridge.com/zh-HK/quote/IONS.US.md)
- [Otsuka Holdings Co., Ltd. (4578.JP)](https://longbridge.com/zh-HK/quote/4578.JP.md)

## 相關資訊與研究

- [Otsuka Holdings Grants Restricted Stock to Directors Tied to Medium-Term Performance Targets](https://longbridge.com/zh-HK/news/280743257.md)
- [Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market](https://longbridge.com/zh-HK/news/280675376.md)
- [Ionis Pharmaceuticals (IONS) Valuation Check As FDA Grants Priority Review For Olezarsen](https://longbridge.com/zh-HK/news/278239371.md)
- [Ionis Pharmaceuticals EVP Eugene Schneider Reports Sale of Common Shares](https://longbridge.com/zh-HK/news/274583290.md)
- [Ionis Pharmaceuticals CFO Elizabeth L. Hougen Reports Sale of Common Shares](https://longbridge.com/zh-HK/news/274583284.md)